Bionik Laboratories Raises $6.2 Million

Bionik Laboratories is an innovative medical-robotics company that develops healthcare solutions for patients with restricted physical mobility.

TORONTO, Feb. 27, 2015 -- Bionik Laboratories Corp. (OTC:DWTPD), a Delaware corporation (the "Company"), announced today that it acquired Bionik Laboratories, Inc., a Toronto corporation ("Bionik Laboratories"), and completed the sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately $6.2 million. Shares of the Company's common stock will continue to be quoted on the OTC Markets under the symbol "DWTPD" until FINRA's approval of the ticker "BNKL."


Bionik Laboratories is an innovative medical-robotics company that develops healthcare solutions for patients with restricted physical mobility.

Peter Bloch, CEO of Bionik Laboratories, stated, "Our team at Bionik Labs is focused and dedicated to deploying cutting edge solutions that will assist mobility impaired people. As a company, we are committed to improving the lives of hundreds of thousands of people and we are excited to be in the forefront of this new and developing technology."

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered, sold or resold absent registration or an applicable exemption from registration under such Act.

The Company intends to file a Current Report on Form 8-K with the Securities and Exchange Commission with more detailed information in accordance with the SEC rules.

About Bionik Laboratories
Founded in 2010 by Michal Prywata and Thiago Caires, Bionik Laboratories (http://www.Bioniklabs.com), a medical device and robotics company, core focus is robotic exoskeleton technology for users with mobility impairments. The technology provides the ability for users to rehabilitate effectively by being able to actually walk with the help of the technology. Bionik Laboratories has researched, developed and tested its primary product, The ARKE, an exoskeleton device that allows paraplegics and other mobility impaired individuals to stand up, walk and rehabilitate in a more effective way than current manual rehabilitation methods.

Featured Product

SCHUNK's New Safety Gripping System EGN

SCHUNK's New Safety Gripping System EGN

With the SLS, SOS, and STO functionalities, the SCHUNK EGN gripping system certified in accordance with DIN EN ISO 13849 enables safe human/machine collaboration. If the production process is interrupted by an emergency shut-off, the SCHUNK EGN goes into either a safely limited speed mode or a safe stop mode depending on the activated protection zone. In contrast to other solutions available on the market, the SCHUNK safety gripping system is continuously powered even in the safe operating stop so that the gripped parts are reliably held even without mechanical maintenance of gripping force. As soon as the protection zone is released, the gripper immediately switches back to the regular operating mode without the system having to be restarted.